The impact of age on genetic testing decisions in amyotrophic lateral sclerosis

Abstract Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative syndrome. In up to 20% of cases, a family history is observed. Although Mendelian disease gene variants are found in apparently sporadic ALS, genetic testing is usually restricted to those with a family history or younger patients with sporadic disease. With the advent of therapies targeting genetic ALS, it is important that everyone treatable is identified. We therefore sought to determine the probability of a clinically actionable ALS genetic test result by age of onset, globally, but using the UK as an exemplar. Blood-derived DNA was sequenced for ALS genes, and the probability of a clinically actionable genetic test result estimated. For a UK subset, age- and sex-specific population incidence rates were used to determine the number of such results missed by restricting testing by age of onset according to UK’s National Genomic Test Directory criteria. There were 6274 people with sporadic ALS, 1551 from the UK. The proportion with a clinically actionable genetic test result ranged between 0.21 [95% confidence interval (CI) 0.18–0.25] in the youngest age group to 0.15 (95% CI 0.13–0.17) in the oldest age group for a full gene panel. For the UK, the equivalent proportions were 0.23 (95% CI 0.13–0.33) in the youngest age group to 0.17 (95% CI 0.13–0.21) in the oldest age group. By limiting testing in those without a family history to people with onset below 40 years, 115 of 117 (98% of all, 95% CI 96%–101%) clinically actionable test results were missed. There is a significant probability of a clinically actionable genetic test result in people with apparently sporadic ALS at all ages. Although some countries limit testing by age, doing so results in a significant number of missed pathogenic test results. Age of onset and family history should not be a barrier to genetic testing in ALS.

[1]  A. Al-Chalabi,et al.  The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis , 2022, Brain : a journal of neurology.

[2]  P. Andersen,et al.  De novo mutations in SOD1 are a cause of ALS , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  Ewout J. N. Groen,et al.  Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology , 2021, Nature Genetics.

[4]  T. Jenkins,et al.  Value of systematic genetic screening of patients with amyotrophic lateral sclerosis , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  N. Pearce,et al.  Motor Neuron Disease Register for England, Wales and Northern Ireland—an analysis of incidence in England , 2020, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[6]  Timothy A. Miller,et al.  Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. , 2020, The New England journal of medicine.

[7]  Annelot M. Dekker,et al.  ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization , 2020, Brain communications.

[8]  D. Burke,et al.  A proposal for new diagnostic criteria for ALS , 2020, Clinical Neurophysiology.

[9]  Melissa J. Landrum,et al.  ClinVar: improvements to accessing data , 2019, Nucleic Acids Res..

[10]  Ashley R. Jones,et al.  C9orf72 intermediate expansions of 24–30 repeats are associated with ALS , 2019, Acta Neuropathologica Communications.

[11]  A. Al-Chalabi,et al.  Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[12]  O. Hardiman,et al.  Determining the incidence of familiality in ALS , 2018, Neurology: Genetics.

[13]  Ashley R. Jones,et al.  Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials , 2017, Neurology.

[14]  A. Al-Chalabi Perspective: Don't keep it in the family , 2017, Nature.

[15]  Annelot M. Dekker,et al.  Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis , 2017, European Journal of Human Genetics.

[16]  Ashley R. Jones,et al.  ATXN2 trinucleotide repeat length correlates with risk of ALS , 2017, Neurobiology of Aging.

[17]  Quan Li,et al.  InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.

[18]  Chris Shaw,et al.  Detection of long repeat expansions from PCR-free whole-genome sequence data , 2016, bioRxiv.

[19]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[20]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[21]  C. Ki,et al.  De novo FUS mutations in 2 Korean patients with sporadic amyotrophic lateral sclerosis , 2015, Neurobiology of Aging.

[22]  N. Pearce,et al.  Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study , 2014, The Lancet Neurology.

[23]  Semyon Kruglyak,et al.  Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms , 2013, Bioinform..

[24]  Olubunmi Abel,et al.  ALSoD: A user‐friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics , 2012, Human mutation.

[25]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[26]  C. Lewis,et al.  Modelling the Effects of Penetrance and Family Size on Rates of Sporadic and Familial Disease , 2011, Human Heredity.

[27]  C. Shaw,et al.  Amyotrophic Lateral Sclerosis/Motor Neuron Disease , 2006 .

[28]  R. Durbin,et al.  The Sequence Ontology: a tool for the unification of genome annotations , 2005, Genome Biology.

[29]  E. Feuer,et al.  Confidence intervals for directly standardized rates: a method based on the gamma distribution. , 1997, Statistics in medicine.

[30]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[31]  A. Al-Chalabi,et al.  Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. , 2006, Journal of neurology.